Breaking News, Financial News

Financial Report: Abbott 2Q

Humira sales continue to drive pharma growth

Abbott 2Q

2Q Revenues: $9.6 billion (+9%)

2Q Earnings: $1.9 billion (+50%)

YTD Revenues: $18.7 billion (+13%)

YTD Earnings: $2.8 billion (+22%)

Comments: Growth in the quarter was driven by a 13% increase in Pharmaceutical sales. Humira sales approached $2.0 billion in the quarter, up 25%. TRILIPIX/TriCor sales were $419 million, up 6%. Kaletra sales were up 14% to $336 million. Niaspan sales were up 17% to $247 million. Lupron sales were up 9% to $205 million. Pediatric Nutritionals accounted for $779 million (+2%) of sales in the quarter and Coronary Stents accounted for $525 million (-2%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters